| Literature DB >> 30421721 |
Bhavesh D Kevadiya1, Brendan M Ottemann1, Midhun Ben Thomas1, Insiya Mukadam2, Saumya Nigam1, JoEllyn McMillan1, Santhi Gorantla1, Tatiana K Bronich2, Benson Edagwa1, Howard E Gendelman3.
Abstract
The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide "optimal" therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.Entities:
Keywords: Alzheimer's disease (AD); Blood brain barrier (BBB); Brain-targeted nanoparticles; Magnetic resonance imaging (MRI); Nanomedicine; Neurodegenerative disorders; Neuroimaging; Neurotheranostics; Parkinson's disease (PD); Single photon emission computed tomography (SPECT/CT); Theranostics
Year: 2018 PMID： 30421721 PMCID： PMC6486471 DOI： 10.1016/j.addr.2018.10.011
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN： 0169-409X Impact factor: 15.470